KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Accumulated Expenses (2023 - 2025)

Biocryst Pharmaceuticals' Accumulated Expenses history spans 8 years, with the latest figure at $126.4 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 11.58% year-over-year to $126.4 million; the TTM value through Dec 2025 reached $126.4 million, up 11.58%, while the annual FY2025 figure was $126.4 million, 11.58% up from the prior year.
  • Accumulated Expenses reached $126.4 million in Q4 2025 per BCRX's latest filing, up from $118.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $126.4 million in Q4 2025 to a low of $75.2 million in Q1 2023.
  • Average Accumulated Expenses over 3 years is $96.8 million, with a median of $97.8 million recorded in 2023.
  • The largest YoY upside for Accumulated Expenses was 34.64% in 2024 against a maximum downside of 5.37% in 2024.
  • A 3-year view of Accumulated Expenses shows it stood at $102.9 million in 2023, then grew by 10.12% to $113.3 million in 2024, then rose by 11.58% to $126.4 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Accumulated Expenses are $126.4 million (Q4 2025), $118.8 million (Q3 2025), and $107.1 million (Q2 2025).